ICON Public Limited Company · ICLR · FY2026 Q2 · Calendar Q3 2026
ICON Reaffirms 2026 Guidance as Bookings and AI Efforts Advance
The current analysis supports a constructive operating trajectory: strong bookings, biotech demand, and AI and laboratory investments are positives, but margin mix, cash use, and the Symphony divestiture temper the outlook.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about ICLR FY2026 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Bookings accelerated from the prior quarter's 22% year-over-year growth to 24%, while net book-to-bill rose from 1.42x to 1.51x. The current analysis added Anthropic and Microsoft AI collaborations and China lab expansion, while pass-through activity became a clearer margin issue.
Guidance delta
Management reaffirmed full-year 2026 revenue and EPS guidance; no change was identified in the supplied analysis.
Key takeaways
- Q2 net bookings rose 24% year over year to $3.1 billion, with a 1.51x net book-to-bill.
- Higher pass-through activity supported revenue but pressured adjusted EBITDA margin.
- AI collaborations with Anthropic and Microsoft, plus China lab expansion, broaden capabilities.
Management priorities
- Scale Orbis, Meridian, and domain-specific AI agents.
- Expand laboratory and specialty biomarker capabilities in China and Singapore.
- Maintain cost discipline while deepening cross-selling to biotech clients.
Follow ICLR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.…
Historical context
All ICLR earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AVTR Avantor, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -2.2% | Avantor reports stronger growth and raises full-year guidance |
| IQV IQVIA Holdings Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.5% | -0.7% | IQVIA: AI momentum and bookings support raised 2026 outlook |
| CNC Centene Corp. | FY2026 Q3 · Calendar Q4 2026 | +506.1% | +1.0% | Centene raises EPS outlook as Medicaid remains stable |
| HCA HCA Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +8.6% | -3.3% | HCA Q3: Volume growth offsets payer-mix and Medicaid pressure |
| RGEN Repligen Corporation | FY2026 Q3 · Calendar Q4 2026 | +14.5% | -2.4% | Repligen: Record Q3, Higher Guidance, BioLife Integration |
| NVS Novartis AG | FY2026 Q3 · Calendar Q4 2026 | +9.3% | +2.0% | Novartis Q3 2026: Growth, Margin Expansion and Higher Guidance |
Latest beats and misses
Who reports nextBeat on EPS
- HLTFY2026 Q3 · October 27, 2026+3.4% EPS-2.1% move
- SPGIFY2026 Q3 · October 27, 2026+3.4% EPS-0.4% move
- PYPLFY2026 Q3 · October 27, 2026+10.7% EPS+2.0% move
- CMSAFY2026 Q3 · October 27, 2026+6.7% EPS0.0% move
- ITWFY2026 Q3 · October 27, 2026+2.4% EPS-0.1% move
- IQVFY2026 Q3 · October 27, 2026+2.5% EPS-0.7% move
Missed on EPS
- ARCCFY2026 Q3 · October 27, 2026-3.4% EPS-0.5% move
- WSOFY2026 Q3 · October 27, 2026-8.0% EPS-1.4% move
- IVZFY2026 Q3 · October 27, 2026-2.7% EPS-0.4% move
- SHWFY2026 Q3 · October 27, 2026-1.6% EPS-2.7% move
- BAFY2026 Q3 · October 27, 2026-33.4% EPS-10.7% move
- AREFY2026 Q3 · October 26, 2026-13401.8% EPS-5.9% move
Get the ICLR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-27T21:03:28.043798+00:00
- FN2 earnings calendar · 2026-09-03T01:23:14.877038+00:00
- Polygon adjusted daily market bars · 2026-10-28T15:40:41.641473+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-28T15:40:41.638658+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-28. For educational purposes only; not investment advice.